Fluorouracil
- Generic Name
- Fluorouracil
- Brand Names
- Actikerall, Carac, Efudex, Fluoroplex, Tolak
- Drug Type
- Small Molecule
- Chemical Formula
- C4H3FN2O2
- CAS Number
- 51-21-8
- Unique Ingredient Identifier
- U3P01618RT
- Background
A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid.
- Indication
For the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Fluorouracil injection is indicated in the palliative management of some types of cancer, including ...
- Associated Conditions
- Actinic Keratosis (AK), Breast Cancer, Colon Cancer, Gastric Cancer, Pancreatic Cancer, Rectal Cancer, Superficial Basal Cell Carcinoma, Verruca (Warts), Hyperkeratotic actinic keratosis
- Associated Therapies
- -
HR070803 in Combination With Oxaliplatin, S-1 Versus NALIRIFOX as Adjuvant Therapy for Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-04-25
- Last Posted Date
- 2024-04-25
- Target Recruit Count
- 120
- Registration Number
- NCT06383078
Photoradiation with Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advanced or Metastatic Pancreatic Cancer
- Conditions
- Interventions
- Procedure: BiopsyProcedure: Biospecimen CollectionProcedure: Computed TomographyProcedure: Endoscopic UltrasoundDrug: FluorouracilDrug: IrinotecanDrug: LeucovorinProcedure: Lymph Node BiopsyProcedure: Magnetic Resonance ImagingDrug: OxaliplatinBiological: PembrolizumabDrug: Photodynamic TherapyProcedure: Positron Emission TomographyOther: Questionnaire AdministrationDrug: Verteporfin
- First Posted Date
- 2024-04-24
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 25
- Registration Number
- NCT06381154
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
Phase II Study of Irinotecan Liposomes in First-line Treatment of Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-04-02
- Last Posted Date
- 2024-08-12
- Lead Sponsor
- West China Hospital
- Target Recruit Count
- 86
- Registration Number
- NCT06341296
- Locations
- 🇨🇳
West China Hospital，Sichuan University, Sichuan, Sichuan, Chengdu, China
Holmium-166 TARE in Liver Limited Unresectable Colorectal Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2024-03-27
- Last Posted Date
- 2024-03-27
- Lead Sponsor
- Gruppo Oncologico del Nord-Ovest
- Target Recruit Count
- 46
- Registration Number
- NCT06332079
- Locations
- 🇮🇹
Azienda Ospedaliero Universitaria Pisana, Pisa, Italy
ELVN-002 with Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer
- First Posted Date
- 2024-03-25
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Enliven Therapeutics
- Target Recruit Count
- 275
- Registration Number
- NCT06328738
- Locations
- 🇧🇪
Cliniques Universitaires Saint-Luc, Brussels, Belgium
🇧🇪CHU de Liège, Liège, Belgium
🇧🇪GZA Ziekenhuizen - Campus Sint-Augustinus, Wilrijk, Belgium
Comparing the Safety and Efficacy of First-line Polychemotherapy and Polychemotherapy in Combination With PIPAC Sessions
- First Posted Date
- 2024-03-15
- Last Posted Date
- 2024-03-15
- Target Recruit Count
- 106
- Registration Number
- NCT06313801
- Locations
- 🇷🇺
Research Institute of Clinical Oncology "Nizhny Novgorod Regional Clinical Oncological Dispensary", Nizhny Novgorod, Russian Federation
Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients
- Conditions
- Interventions
- First Posted Date
- 2024-02-28
- Last Posted Date
- 2024-03-04
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 156
- Registration Number
- NCT06280495
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Intraperitoneal Oxaliplatin and Fluorouracil for the Treatment of Patients With Peritoneal Metastases From Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-02-21
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- Arjun Mittra
- Target Recruit Count
- 24
- Registration Number
- NCT06269978
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Botensilimab and Balstilimab Optimization in Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-02-20
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Nicholas DeVito, MD
- Target Recruit Count
- 15
- Registration Number
- NCT06268015
- Locations
- 🇺🇸
Duke University, Durham, North Carolina, United States
Stereotactic Body Radiation Therapy Followed by NALIRIFOX vs NALIRIFOX for Borderline Resectable Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-02-14
- Last Posted Date
- 2024-03-15
- Target Recruit Count
- 96
- Registration Number
- NCT06259058
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.